Gilead Sciences: Pipeline Products Performance Potential

Publication Date	February 2008
Publisher	Espicom
Product Type	Report
Pages	76
ISBN Number	not applicable
Product Code	ESP00328

Price

£595.00
approximately: $884 | €700

PDF

Order above formats by FAX

Summary

Pharmaceutical Company Intelligence Reports from Espicom Provide A Full Review of The Company's Activities Together with Five-Year Sales Forecasts for Its Key Products. The Company's Financial Performance Is Covered in-Depth, from Its Latest Results to A Complete Analysis of Its Latest Full Fiscal Year and An Outlook for The Future. A Section on Company Strategy Covers Mergers, Acquisitions and Divestitures, Key Agreements, Products and R&d. An Overview of Key Products and R&d Is Followed by A Comprehensive Review of The Company's Product Portfolio and Research and Development Pipeline by Therapeutic Area. in Addition, Supplementary Appendices Provide More in-Depth Information on Financials, Agreements and Corporate Events.

Content

Latest Results
Executive Summary
Introduction
Current Financial Position
Company Performance
Business Segment Performance
Geographic Segment Performance
- Company Strategy
Mergers, Acquisitions and Divestitures
Key Agreements
Employees
- Product Performance Forecasts
- Pipeline Analysis
- Conclusions/Outlook
- Therapeutic Area Focus
- R&d Pipeline
- Antiviral
- Marketed Products
- Atripla
- Truvada
- Viread
- Others
Hepatitis
- Hepsera
- R&d Projects
- Elvitegravir (Gs 9137)
- Gs 9131
Hepatitis
- Gs 9190
Discontinued R&d Projects
- Growth Forecast
Hepatitis
- Others
- Marketed Products
- Ambisome
- Letairis
- Others
- R&d Projects
- Aztreonam Lysine
- Darusentan
- Gs 59450
- Gs 9310/11
- Growth Forecast
Appendix 1 - Financial Performance
Appendix 2 - Key Corporate Events
Appendix 3 - Key Agreements
- 4aza Bioscience
- Achillion Pharmaceuticals
- Anadys Pharmaceuticals
- Aspen Pharmacare
- Astellas Pharma
- Bristol-Myers Squibb
- Dainippon Sumitomo Pharma
- Diatos
- Emory University/Royalty Pharma
- Genelabs Technologies
- Gladstone Institute of Virology and
- Immunology
- Glaxosmithkline
- International Partnership for
- Microbicides/Conrad
- Japan Tobacco
- Lg Life Sciences Ltd
- Merck & Co
- Novartis
- Parion Sciences Inc
- Roche
Appendix 4 - Infrastructure
- Research and Development Facilities
- Manufacturing Facilities
Appendix 5 - Key Pharmaceutical
- Subsidiaries / Joint Ventures
- Subsidiaries
- Joint Ventures
Index of Tables
- Principal Operating Results
- R&d Expenditure
- Sales by Destination
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Hiv Products, 2007
- Major Hepatitis Products, 2007
- Major Other Area Products, 2006
Index of Charts
- R&d Expenditure, 2007
- Sales by Destination
- Sales of Top Five Products (2004a-2012e)
- Top Selling Products, 2007
- Atripla Sales (2006a-2012e)
- Truvada Sales (2004a-2012e)
- Viread Sales (2002a-2012e)
- Gilead Sciences
- Hepsera Sales (2002a-2012e)
- Gs 9137 Sales (2009a-2013e)
- Hiv Product Portfolio Forecast (2006a-2011e)
- Ambisome Sales (2001a-2011e)
- Aztreonam Sales (2008e-2012e)
- Darusentan Sales (2009e-2013e)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&d Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity